» Articles » PMID: 27011677

Nucleic Acid Testing: Is It the Only Answer for Safe Blood in India?

Overview
Specialty Hematology
Date 2016 Mar 25
PMID 27011677
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the implementation of NAT in countries around the world, there is a growing pressure on the transfusion services in India to adopt NAT testing. India has about 2545 licensed Blood Centres. The Transfusion Services in India are fragmented, poorly regulated and the quality standards are poorly implemented. Blood Centres are still dependent on replacement/family donors and in most places laboratory testing for Transfusion transmitted infections is not quality assured, laboratory equipment are not calibrated and maintained, and validation of results is not carried out. Against the current scenario introducing NAT for screening of blood donors in India would pose a challenge.

Aim: To study the prudence of universal NAT testing in India.

Materials And Methods: A retrospective study of 5 years from 2008-2012 was undertaken to study the true reactivity of donors using WHO strategy II and III and therefore the true seroprevalence of TTI infections in the donor populations.

Results: The true reactivity of the donors was much less as compared to the initially reactive donors due to the use of a well designed testing algorithm. In addition having a total voluntary blood collection along with good pre-donation counseling program also reduces the transmission of infections.

Conclusions: What India essentially needs to do is religiously implement the strategies outlined in the WHO Aide-memoire. The blood should be collected only from voluntary non remunerative and repeat donors, there should be stringent donor selection with pre-donation counseling instituted. Strict implementation of quality management system, development of well defined testing startegies and strong haemovigilance system could take us a step in the right direction.

Citing Articles

Efficacy of combined HBsAg, anti-HBc and anti-HBs screening in minimizing transfusion transmission risk of hepatitis B infection in low resource setting.

Athalye S, Patil A, Khargekar N, Shinde S, Chavan S, Dixit A Heliyon. 2024; 10(3):e25805.

PMID: 38356514 PMC: 10865305. DOI: 10.1016/j.heliyon.2024.e25805.


Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience.

Pathak A, Panda D, Sharma M, Tejwani N, Mehta A Indian J Hematol Blood Transfus. 2023; 39(3):456-463.

PMID: 37304490 PMC: 10247654. DOI: 10.1007/s12288-022-01598-y.

References
1.
Busch M, Korelitz J, Kleinman S, Lee S, Aubuchon J, Schreiber G . Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion. 1995; 35(11):903-10. DOI: 10.1046/j.1537-2995.1995.351196110893.x. View

2.
Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M . A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion. 2010; 51(4):719-30. DOI: 10.1111/j.1537-2995.2010.02942.x. View

3.
Stramer S . Nucleic acid testing for transfusion-transmissible agents. Curr Opin Hematol. 2000; 7(6):387-91. DOI: 10.1097/00062752-200011000-00011. View

4.
Ling A, Robbins K, Brown T, Dunmire V, Thoe S, Wong S . Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA. 2000; 284(2):210-4. DOI: 10.1001/jama.284.2.210. View

5.
Basavaraju S, Mwangi J, Nyamongo J, Zeh C, Kimani D, Shiraishi R . Reduced risk of transfusion-transmitted HIV in Kenya through centrally co-ordinated blood centres, stringent donor selection and effective p24 antigen-HIV antibody screening. Vox Sang. 2010; 99(3):212-9. DOI: 10.1111/j.1423-0410.2010.01340.x. View